Projecting a maximum future price target for Cybin—operating as Helus Pharma—is speculative because equity valuations in the clinical-stage biotechnology sector depend on unpredictable variables such as clinical trial outcomes, regulatory approvals, capital market conditions, and future commercialization success. Wall Street equity analysts issue fluctuating twelve-month price targets based on discounted cash flow models and pipeline probability assessments, but these targets change frequently. If the company successfully advances its late-stage clinical candidates through regulatory approval and establishes a commercial market presence, its valuation could scale significantly; conversely, negative clinical data or funding challenges can deflate equity prices.